Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 389 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Open-angle Glaucoma Clear all
Terminated Phase 4 Interventional

A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy

NCT00597181
View directory record Official record
Conditions
Glaucoma
Interventions
Trabeculectomy with mitomycin c, Ex-Press mini shunt with mitomycin c
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

NCT00945958
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0913
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 4 Interventional

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

NCT00300079
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
brinzolamide 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 5, 2026, 7:15 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Optic Nerve Head Strain as Biomarker for Glaucoma

NCT06240312
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Images of eye at 2 eye pressures
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 5, 2026, 7:15 PM EDT
Not listed Phase 3 Interventional

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
Drug
Lead sponsor
TearClear Corp
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 5, 2026, 7:15 PM EDT
Recruiting Not applicable Interventional

Electrical Stimulation for the Treatment of Optic Neuropathies

NCT05626426
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases
Interventions
Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 5, 2026, 7:15 PM EDT
Not listed No phase listed Observational

iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study

NCT04624685
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Not listed
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
24
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 3 Interventional

SOLX Titanium Sapphire Laser for Trabeculoplasty

NCT00145535
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open Angle
Interventions
SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT)
Device
Lead sponsor
SOLX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
Petaluma, California • Tampa, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Sep 5, 2026, 7:15 PM EDT
Terminated Not applicable Interventional Results available

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

NCT01828255
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG) Patient
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
40 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 5, 2026, 7:15 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

NCT06369077
View directory record Official record
Conditions
Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions
dorzolamide/timolol
Drug
Lead sponsor
CT Glaucoma Associates
Other
Eligibility
25 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01215786
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Drug Delivery System in Glaucoma

NCT01016691
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 3 Interventional

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

NCT00047528
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Alcon Investigational Agent
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

NCT02622334
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04742283
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 5, 2026, 7:15 PM EDT
Terminated Phase 1 Interventional

Safety Study of Latanoprost Slow Release Insert

NCT01180062
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Latanoprost, Arm 2, Latanoprost SR insert
Drug
Lead sponsor
Daniel Moore
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01707381
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
BOL-303259-X, Timolol maleate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
40 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 5, 2026, 7:15 PM EDT
Not listed Not applicable Interventional

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

NCT05280366
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Streamline Surgical System, iStent Inject W
Device
Lead sponsor
New World Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
18
States / cities
Fayetteville, Arkansas • Newport Beach, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 2 Interventional

Next Generation Rocklatan

NCT06441643
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 2 Interventional

Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma

NCT00317577
View directory record Official record
Conditions
Glaucoma, Open Angle
Interventions
brimonidine, timolol
Drug
Lead sponsor
Chicago Center for Vision Research
Other
Eligibility
30 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
12
States / cities
Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2006 · Synced Sep 5, 2026, 7:15 PM EDT
Withdrawn No phase listed Observational

Prevalence of Dyschromatopsia in Glaucoma Patients

NCT01994564
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Sep 5, 2026, 7:15 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Outcomes in Cataract Surgery With OMNI Canaloplasty vs Cataract Surgery With OMNI Canaloplasty and Hydrus Stent

NCT05949242
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI canaloplasty, Hydrus microstent
Device
Lead sponsor
Ridge Eye Care
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
4
States / cities
Marysville, California • Oroville, California • Paradise, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT01687426
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
Brimonidine Tartrate 0.025%, Vehicle
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Sep 5, 2026, 7:15 PM EDT